Output strategies and import costs imply that CBMPs are usually expensive, introducing even further to high research costs [eighteen]. Research has therefore centered on compounds beneath patent rather than generic CBMPs where research results fail to deliver an identical return on investment decision for licensed producers and pharmaceutical compa